Linkedin Facebook Twitter Youtube

18 Jul RheumaGen

Posted at 20:09h in by

Richard Freed, CEO

Oct. 8 | 10:00am | FLW Ballroom F

Aurora, CO

(Private)

RheumaGen is a private biotechnology company engineering a new class of therapeutics to cure major autoimmune diseases. RheumaGen focuses on editing the human leukocyte antigen (HLA) gene, or “immune gene,” to develop one-time, curative cell and gene therapies. We are building a pipeline of treatments to address autoimmune diseases in which HLA alleles play a critical epidemiological role, including programs for multiple sclerosis, type 1 diabetes, and ankylosing spondylitis currently in development. In December 2024, we closed a $15M Series A financing that will support RheumaGen in completing a Phase I clinical trial of our lead program, RG0401, for treatment-resistant or refractory rheumatoid arthritis (RA). RheumaGen is headquartered in Aurora, Colorado.

www.rheumagen.com



About the Event

The Cell & Gene Meeting on the Mesa is the sector’s foremost annual conference bringing together senior executives and top decision-makers in the industry to advance cutting-edge research into cures. Tackling the commercialization hurdles facing the cell and gene therapy sector today, this meeting covers a wide range of topics from clinical trial design to alternative payment models to scale-up and supply chain platforms for advanced therapies. The program features expert-led panels, extensive partnering capabilities, exclusive networking opportunities, and 110+ dedicated presentations by the leading publicly traded and privately held companies in the space. Attracting over 1,500 attendees – over 30% of which are C-level executives – this conference enables key partnerships through more than 5,000 one-on-one meetings while highlighting the significant clinical and commercial progress in the field.

Dates & Location

October 5-7, 2026
Arizona Biltmore
Phoenix, AZ

Program Organizer

By using this website you agree to accept our Privacy Policy and Terms & Conditions